IP Library Patent Application 19225492
Patent Application
App. No. 19/225,492

METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/225,492
Abstract

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

Claims (33)

1 . A method for treating a patient suffering from vitiligo, comprising topically administering to said patient a composition comprising:

(i) roflumilast in an amount of 0.05%-1% w/w, and

(ii) a phosphate ester surfactant blend comprising cetostearyl alcohol, dicetyl phosphate and ceteth-10 phosphate in an amount of 1.0-25% w/w.

2 . The method of claim 1 , wherein said roflumilast is in an amount of 0.05% w/w.

3 . The method of claim 1 , wherein said roflumilast is in an amount of 0.15% w/w.

4 . The method of claim 1 , wherein said roflumilast is in an amount of 0.3% w/w.

5 . The method of claim 1 , wherein said composition is a cream, wherein said roflumilast is present in an amount 0.3% w/w, wherein said phosphate ester surfactant blend is present in an amount of 2.5%-20% w/w, and wherein said composition further comprises diethylene glycol monoethyl ether and water.

6 . The method of claim 5 , wherein said phosphate surfactant blend is present in an amount of 5%-15% w/w.

7 . The method of claim 6 , wherein said phosphate surfactant blend is present in an amount of 10% w/w.

8 . The method of claim 5 , wherein said composition further comprises hexylene glycol in an amount of 0.1-20% w/w.

9 . The method of claim 5 , wherein said composition further comprises at least one additional component selected from the group consisting of a solvent, moisturizer, preservative, pH adjusting solution, and skin penetration enhancer.

10 . The method of claim 1 , wherein said composition is a cream, wherein said phosphate surfactant blend is present in an amount of 2.5%-20% w/w, and wherein said composition further comprises diethylene glycol monoethyl ether and water.

11 . The method of claim 10 , wherein said phosphate surfactant blend is present in an amount of 5%-15% w/w.

12 . The method of claim 11 , wherein said phosphate surfactant blend is present in an amount of 10% w/w.

13 . The method of claim 10 , wherein said composition further comprises hexylene glycol in an amount of 0.1-20% w/w.

14 . The method of claim 10 , wherein said composition further comprises at least one additional component selected from the group consisting of a solvent, moisturizer, preservative, pH adjusting solution, and skin penetration enhancer.

15 . The method of claim 1 , wherein said composition is a cream, wherein said roflumilast is present in an amount 0.05% w/w, wherein said phosphate surfactant blend is present in an amount of 2.5%-20% w/w, and wherein said composition further comprises diethylene glycol monoethyl ether and water.

16 . The method of claim 15 , wherein said phosphate surfactant blend is present in an amount of 5%-15% w/w.

17 . The method of claim 16 , wherein said phosphate surfactant blend is present in an amount of 10% w/w.

18 . The method of claim 15 , wherein said composition further comprises hexylene glycol in an amount of 0.1-20% w/w.

19 . The method of claim 15 , wherein said composition further comprises at least one additional component selected from the group consisting of a solvent, moisturizer, preservative, pH adjusting solution, and skin penetration enhancer.

20 . A method for treating a patient suffering from vitiligo, comprising topically administering to said patient a composition comprising:

(i) roflumilast in an amount of 0.05%-1% w/w;

(ii) a surfactant;

(iii) a solvent; and

(iv) water.

21 . The method of claim 20 , wherein said roflumilast is in an amount of 0.3% w/w.

22 . The method of claim 20 , wherein said roflumilast is in an amount of 0.15% w/w.

23 . The method of claim 20 , wherein said roflumilast is in an amount of 0.05% w/w.

24 . The method of claim 20 , wherein the surfactant is a phosphate ester surfactant blend comprising cetostearyl alcohol, dicetyl phosphate and ceteth-10 phosphate in an amount of 1.0-25% w/w.

25 . The method of claim 20 , wherein the solvent is diethylene glycol monoethyl ether.

26 . The method of claim 20 , wherein said composition further comprises hexylene glycol in an amount of 0.1-20% w/w.

27 . The method of claim 20 , wherein said composition further comprises at least one additional component selected from the group consisting of a moisturizer, preservative, pH adjusting solution, and skin penetration enhancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2026
From: OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 073592/0097 →